| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 07/11/2002 | WO2002053525A1 Perfluoronated cycle-containing tertiary amines used as a basis for gas-conveying emulsions and device for the production thereof |
| 07/11/2002 | WO2002053288A2 A method for the manufacture of compositions containing low concentrations of salts |
| 07/11/2002 | WO2002053167A2 Pharmaceutical combination for the treatment of tissue damage owing to an arterial irrigation defect |
| 07/11/2002 | WO2002053110A2 Pharmaceutical preparation for douches and/or irrigations of natural or pathological cavities in the human body |
| 07/11/2002 | WO2002053100A2 Pharmaceutical dosage form for oral administration of low molecular weight heparin |
| 07/11/2002 | WO2002034705A3 C-nitroso compounds and use thereof |
| 07/11/2002 | WO2002032446A3 Use of neutrophil inhibitory factor in combination with other thrombolytic or neuroprotective drugs for treating pathophysiological conditions involving neutrophils |
| 07/11/2002 | WO2002020724A3 Adenoviral targeting and manipulation of immune system response using targeting peptides |
| 07/11/2002 | WO2001096311A3 Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases |
| 07/11/2002 | WO2001077377A3 Diagnosis of diseases associated with dna replication by assessing dna methylation |
| 07/11/2002 | WO2001076593A3 Bile secretion promoting composition a 15-keto prostaglandin |
| 07/11/2002 | WO2001046443A3 Proteases |
| 07/11/2002 | WO2001044473A3 Polypeptides and nucleic acids encoding same |
| 07/11/2002 | WO2001034225A3 Hyperoncotic artificial cerebrospinal fluid and method of treating neural tissue edema therewith |
| 07/11/2002 | WO2001008669A3 Therapeutic agents for lymphoedema |
| 07/11/2002 | US20020091263 Biaryl substituted purine derivatives as potent antiproliferative agents |
| 07/11/2002 | US20020091143 Use of 4-substituted tetrahydropyridines for the manufacture of medicament s acting upon TGF-beta 1 |
| 07/11/2002 | US20020091105 Useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. |
| 07/11/2002 | US20020091089 (Substituted)acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases |
| 07/11/2002 | US20020090715 Method for the preparation of a viral vector by inter-molecular homologous recombination |
| 07/11/2002 | US20020090388 Implantable, for sustained delivery of a drug directly into systemic circulation of an animal |
| 07/11/2002 | US20020090368 Therapeutic uses of bactericidal/permeability increasing (BPI) protein products |
| 07/11/2002 | DE10064195A1 Verwendung einer Zusammensetzung zur Stimulation des Nervenwachstums, zur Inhibition der Narbengewebsbildung und/oder Reduktion eines Sekundärschadens Use of a composition for the stimulation of nerve growth, to inhibition of scar tissue formation and / or reduction of secondary damage |
| 07/11/2002 | CA2789161A1 Pharmaceutical composition to prevent tissue damage due to arterial blood flow failure |
| 07/11/2002 | CA2433580A1 Tertiary perfluorocycloamines as a basis for gas transport emulsions and process for preparing thereof |
| 07/11/2002 | CA2433552A1 Pharmaceutical preparation for douches and/or irrigations of natural or pathological cavities in the human body |
| 07/11/2002 | CA2433225A1 Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| 07/11/2002 | CA2432853A1 Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| 07/11/2002 | CA2431662A1 A method for the manufacture of compositions containing low concentrations of salts |
| 07/10/2002 | EP1221477A2 Transfection of vertebrate cells e.g. by homologous recombination |
| 07/10/2002 | EP1221440A1 Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators |
| 07/10/2002 | EP1221439A1 Tetrahydroquinoline derivatives |
| 07/10/2002 | EP1220947A2 50 human secreted proteins |
| 07/10/2002 | EP1220942A1 41 human secreted proteins |
| 07/10/2002 | EP1220923A2 FACTOR IX/FACTOR IXa ANTIBODIES AND ANTIBODY DERIVATIVES |
| 07/10/2002 | EP1220920A1 The prv-1 gene and use thereof |
| 07/10/2002 | EP1220865A1 43 human secreted proteins |
| 07/10/2002 | EP1220852A1 Substituted diazepans |
| 07/10/2002 | EP1220845A1 Aryl-sulfonamide substituted benzimidazol derivatives and use of said as tryptase inhibitors |
| 07/10/2002 | EP1220693A1 Formulations for delivery of osteogenic proteins |
| 07/10/2002 | EP1220685A2 Pharmaceutical compositions of fibrinolytic agent |
| 07/10/2002 | EP1220661A2 Transdermal therapeutic system for administering acetylsalicylic acid and/or salicylic acid |
| 07/10/2002 | EP0970130B1 Glycosaminoglycans having high antithrombotic activity |
| 07/10/2002 | EP0914158B1 Pharmaceutical combination containing a compound having angiotensin ii antagonistic activity and a compound which increases the insulin-sensitivity |
| 07/10/2002 | CN1358195A Inhibitors of integrin alpha V beta 6 |
| 07/10/2002 | CN1358193A Steroid compounds with C17-alkyl side chain and aromatic A-ring for use in therapy |
| 07/10/2002 | CN1358191A N-pyrazole A2A receptor agonists |
| 07/10/2002 | CN1358190A Propargyl phenyl ether A2A receptor agonists |
| 07/10/2002 | CN1358189A C-2A pyrazole A2A receptor agonists |
| 07/10/2002 | CN1358187A New compounds |
| 07/10/2002 | CN1358179A Thiazole and oxazole derivatives and their pharmaceutical use |
| 07/10/2002 | CN1358174A New Compounds |
| 07/10/2002 | CN1358062A 巨噬细胞清除剂受体拮抗剂 Macrophage scavenger receptor antagonists |
| 07/10/2002 | CN1357541A Phosphatidase A2 inhibitor and its prepn process and use |
| 07/10/2002 | CN1357340A Snake blood prepn for treating hemopathy |
| 07/09/2002 | US6417393 Treatment of sickle-cell anemia, brain edema from tumors or ischemia, diarrhea, and glaucoma; hypotensive, wound healing, antiinflammatory and antiallergen agents |
| 07/09/2002 | US6417371 Process for preparing 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl-acetic acid |
| 07/09/2002 | US6417329 Purified polypeptide |
| 07/09/2002 | US6417227 Methods of delivery of cetyl myristoleate |
| 07/09/2002 | US6417204 Cardiovascular disoders |
| 07/09/2002 | US6417200 Antithrombotic agents |
| 07/09/2002 | US6417161 Amino acid amidinohydrazones, alkoxyguanidines and aminoguanidines as protease inhibitors |
| 07/09/2002 | US6416991 Genetic engineered protein |
| 07/09/2002 | US6416956 Screening for and/or diagnosing breast cancer by obtaining cell sample from patient and determining whether bp1 is overexpressed by said cell sample as compared to normal cells |
| 07/09/2002 | CA2048212C Sulfonamide derivatives |
| 07/08/2002 | CA2366780A1 Stabilized liquid preparation of the protease which activates blood coagulation factor vii, or of its proenzyme |
| 07/04/2002 | WO2002051844A1 Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands |
| 07/04/2002 | WO2002051831A1 Oxybenzamides derivatives as factor xa inhibitors |
| 07/04/2002 | WO2002051824A1 Amidinophenylalanine derivatives as thrombin inhibitors |
| 07/04/2002 | WO2002051814A1 Benzoylpyridazines |
| 07/04/2002 | WO2002051460A2 Bioactive materials for aneurysm repair |
| 07/04/2002 | WO2002051445A2 An oral and parenteral pharmaceutical formulation comprising a low molecular weight thrombin inhibitor prodrug |
| 07/04/2002 | WO2002051442A1 Concomitant drugs |
| 07/04/2002 | WO2002051429A2 Use of a composition for the stimulation of nerve growth, the inhibition of scar tissue formation, the reduction of secondary damage and/or the accumulation of macrophages |
| 07/04/2002 | WO2002051412A1 Medicinal compositions containing aspirin |
| 07/04/2002 | WO2002051351A2 Antithrombotic von willebrand factor (vwf) collagen bridging blockers |
| 07/04/2002 | WO2002033100A3 Regulation of human adenylate cyclase, type iv |
| 07/04/2002 | WO2002028347A3 Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them |
| 07/04/2002 | WO2002026233B1 Infusion of ciprofloxacin having reduced acid content and being stable in storage |
| 07/04/2002 | WO2002003991A3 Use of substituted indole compounds for increasing nitric oxide synthase activity |
| 07/04/2002 | WO2001090148A8 Neurotransmitter transporters |
| 07/04/2002 | WO2001078768A3 Targeted vaccine delivery systems |
| 07/04/2002 | WO2001077169A3 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| 07/04/2002 | WO2001077097A3 Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade |
| 07/04/2002 | WO2001064886A3 Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| 07/04/2002 | WO2001064652A9 Substituted 5-methyldihydropyridazinones and their use in the prophylaxis and/or treatment of anemias |
| 07/04/2002 | WO2001041791A9 Contortrostatin (cn) and methods for its use in preventing metastasis and other conditions |
| 07/04/2002 | WO2000069897A9 Modulation of glgf motif (dhr/pdz) containing proteins interaction with cd3n in t lymphocytes |
| 07/04/2002 | US20020087205 Transcutaneous photodynamic treatment of targeted cells |
| 07/04/2002 | US20020086872 Anticoagulants; may be embedded in or physically linked to materials used in manufacture of devices used in blood collection, circulation, stents |
| 07/04/2002 | US20020086866 Quinoxalinones as serine protease inhibitors |
| 07/04/2002 | US20020086059 Dissolving solid material in dimethyl ether under a pressure and heating; reducing pressure on solution to precipitate the solid material as pulverous formulation and to expand dimethyl ether into a gas, separating |
| 07/04/2002 | DE10063294A1 New N-(heterocyclyl-alkyl)-fused norbornylamine derivatives, are NHE3 inhibitors useful e.g. for treating respiratory disorders, renal failure, intestinal dysfunction, lipid metabolism disorders or proliferative diseases |
| 07/04/2002 | CA2436739A1 Combination agent |
| 07/04/2002 | CA2433081A1 Bioactive materials for aneurysm repair |
| 07/04/2002 | CA2432644A1 Pharmaceutical composition comprising aspirintm and cs-747 |
| 07/03/2002 | EP1219711A2 Lawsonia intracellularis vaccine |
| 07/03/2002 | EP1219636A2 Modified muteins of erythropoietin (EPO) derived from in vitro or in vivo expression system of microorganisms |
| 07/03/2002 | EP1219302A1 Trapping agent for blood carbonyl compounds |
| 07/03/2002 | EP1218544A1 Methods for identifying rna binding compounds |